报价延迟最少15分钟:2025/09/12 04:14 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
144.36
|
|
|
| 价值评估 |
|
盈利(现时/预测)
4.92/6.70
|
|
企业价值
3.98B
|
| 资产负债 |
|
每股账面净值
35.96
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
290.52M
|
|
每股收益
0.30
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/12 04:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
